Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 35Leukemia 34Small Cell Lung Carcinoma 33Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lung Neoplasms 24Lymphoma, Large B-Cell, Diffuse 19Neuroblastoma 15Lymphoma, Non-Hodgkin 15Carcinoma, Non-Small-Cell Lung 14Leukemia, Erythroblastic, Acute 13Hodgkin Disease 13Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Sarcoma 11Lymphoma, Follicular 10Burkitt Lymphoma 10Lymphoma, Large-Cell, Immunoblastic 9Testicular Neoplasms 7Teratoma 7Myelodysplastic Syndromes 7Congenital Abnormalities 7Multiple Myeloma 6Endodermal Sinus Tumor 6Anemia, Refractory, with Excess of Blasts 6Testicular Germ Cell Tumor 5Ovarian Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Central Nervous System Neoplasms 5

Interventions

apatinib 1PE regimen 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Progression Free Survival × Etoposide × Clear all
NCT03100955 2017-04-04

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Qingdao University

Phase 3 Unknown
120 enrolled

Progression Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡